"Cancer"

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

Oesophageal cancer is a disease that causes a series of symptoms in our body, and it can be said to be a disease that seriously affects our health.

Diseases have certain effects on the body, so it is necessary to learn more about common diseases so that you will know how to diagnose them when symptoms occur.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).

If pancreatic cancer is not treated in time, it will develop and become more and more serious as the disease progresses, and because the symptoms of pancreatic cancer are sometimes not obvious in the early stages of the disease, the disease is diagnosed in the middle and late stages.

Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.